Skip to main content
. 2018 May 10;10(5):730–737. doi: 10.1080/19420862.2018.1463945

Figure 1.

Figure 1.

Increased production of anti-CLDN1 B9x IgG4 by transient and stable expression of the SINEUP-40+32 construct>. A. The ELISA assay shows increased production of full human B9x IgG4 in cells co-transfected with the construct expressing the SINEUP-40+32 lncRNA, targeting both heavy- and light-chain mRNAs of the anti-CLDN1 B9x antibody. B. The ELISA assay, revealing full human IgGs, shows the antibodies secreted by HEK293E (wt) and HEK293E_SINEUP-40+32 cells stably expressing the lncRNA (pool or isolated clones 1, 3, 12, 15) after 8 days following transfection with pEUVH8.2_B9x and pEUVL4.2_SA_B9x vectors. The asterisks indicate p values < 0.05 (compared to wt cells). C. The panel shows the levels of SINEUP-40+32 lncRNA transcripts in HEK293E (wt) cells and in HEK293E_SINEUP-40+32 clones. D. The chart reports the results of a correlative analysis of anti-CLDN1 B9x mAb production (y axis) against relative levels of SINEUP-40+32 lncRNA transcripts (x axis). B9x expression data used for comparisons were averaged from the whole set of results shown in the panel B of the Figure.